It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Tumour detection with high selectivity and sensitivity is crucial for delineating tumour margins and identifying metastatic foci during image-guided surgery. Optical nanoprobes with preferential tumour accumulation is often limited by inefficient amplification of biological signals. Here, we report the design of a library of hydrophobic core-tunable ultra-pH-sensitive nanoprobes (HUNPs) for orthogonally amplifying tumour microenvironmental signals on multiple tumour models. We find that tuning the hydrophobicity of nanoparticle core composition with non-ionizable monomers can enhance cellular association of HUNPs by more than ten-fold, resulting in a high cellular internalization efficiency of HUNPs with up to 50% in tumours. Combining high tumour accumulation and high cell internalization efficiency, HUNPs show orthogonally amplified fluorescence signals, permitting the precise locating and delineating margins between malignant lesions and normal tissues with high contrast-to-noise ratio and resolution. Our study provides key strategies to design nanomedicines with high intracellular bioavailability for cancer detection, drug/gene delivery, and therapy.
Optical nanoprobes with preferential tumour accumulation is often limited by inefficient amplification of biological signals. Here, the authors report a hydrophobic core-tunable nanoprobe orthogonally amplifying tumour microenvironmental signals and demonstrating clear delineation between malignant lesions and normal tissues on multiple tumour models.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Peking University, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Beijing, China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319); Peking University, Beijing Key Laboratory of Molecular Pharmaceutics, School of Pharmaceutical Sciences, Beijing, China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319)
2 Peking University, Beijing Key Laboratory of Molecular Pharmaceutics, School of Pharmaceutical Sciences, Beijing, China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319)
3 Peking University, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Beijing, China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319); Peking University, Beijing Key Laboratory of Molecular Pharmaceutics, School of Pharmaceutical Sciences, Beijing, China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319); Peking University, Chemical Biology Center, Beijing, China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319)